CRISPR Therapeutics Soars 50% on First Approval and Pipeline Potential; Pfizer Stock Tempts Income Investors Despite COVID Slump
• CRISPR Therapeutics stock has advanced 50%+ in 2023 due to first product approval and potential blockbuster treatment for blood disorders
• Casgevy sales will provide CRISPR's first product revenue; more pipeline candidates could drive further growth
• Pfizer stock is cheap (P/E 9.8) and pays high dividend (6% yield) despite down year due to COVID product sales slump
• Pfizer has growth drivers that could fuel rebound once COVID product sales stabilize
• CRISPR better for growth investors seeking revenue increases; Pfizer appeals more to income/value investors